This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ganesh, S. Articles by Verspaget, H. W. Search for Related Content PubMed PubMed Citation Articles by Ganesh, S. Articles by Verspaget, H. W.

Prognostic Relevance of Plasminogen Activators and Their Inhibitors in Colorectal Cancer¹

Departments of Gastroenterology and Hepatology [S. G., C. F. M. S., G. G., H. J. M. V., C. B. H. W. L., H. W. V.], Clinical Epidemiology [A. d. B.], Surgery [K. W., C. J. H. v. d. V.], and Pathology [J. H. J. M. v. K.], University Hospital Leiden, P.O. Box 9600, 2300 RC Leiden, and Gaubius Laboratory TNO-PG [J. H. V.], Leiden, the Netherlands

Human colorectal carcinogenesis has been shown previously to be associated with impressive changes in the tissue levels of plasminogen activators and their inhibitors, exemplified by an increase in the urokinase-type plasminogen activator (u-PA) and the inhibitors PAI-1 and PAI-2, and a decrease in tissue-type plasminogen activator (t-PA). In the present study we evaluated the prognostic significance of these parameters to the overall survival of patients with colorectal cancer, in conjunction with several major clinicopathological parameters like age, gender, differentiation grade, and Dukes' stage. Univariate analyses revealed that a low t-PA antigen level, low t-PA activity, and high u-PA/t-PA antigen ratio in normal mucosa and a high u-PA and PAI-2 antigen level in carcinomas are prognostic for a poor overall survival of patients with colorectal cancer. The prognostic value of t-PA antigen and activity in normal mucosa, the antigen ratio of u-PA in carcinoma (C) and t-PA in corresponding normal (N) mucosa [u-PA(C)/t-PA(N) antigen ratio], and PAI-2 antigen in carcinomas was found to be independent from clinicopathological parameters by multivariate analyses. These observations illustrate the clinical importance of the plasminogen activation cascade at the tissue level in colorectal cancer invasion, metastasis, and survival.

¹ This study was supported by a grant from the Dutch Cancer Society (KWF, oaa-92/18).

² To whom requests for reprints should be addressed.

Received 7/ 7/93. Accepted 6/ 1/94.

This article has been cited by other articles:

				G. Konecny, M. Untch, J. Arboleda, C. Wilson, S. Kahlert, B. Boettcher, M. Felber, M. Beryt, S. Lude, H. Hepp, et al. HER-2/neu and Urokinase-Type Plasminogen Activator and Its Inhibitor in Breast Cancer Clin. Cancer Res., August 1, 2001; 7(8): 2448 - 2457. [Abstract] [Full Text] [PDF]

				G. Konecny, M. Untch, A. Pihan, R. Kimmig, M. Gropp, P. Stieber, H. Hepp, D. Slamon, and M. Pegram Association of Urokinase-Type Plasminogen Activator and Its Inhibitor with Disease Progression and Prognosis in Ovarian Cancer Clin. Cancer Res., June 1, 2001; 7(6): 1743 - 1749. [Abstract] [Full Text] [PDF]

				M. N. Holten-Andersen, R. W. Stephens, H. J. Nielsen, G. Murphy, I. J. Christensen, W. Stetler-Stevenson, and N. Brunner High Preoperative Plasma Tissue Inhibitor of Metalloproteinase-1 Levels Are Associated with Short Survival of Patients with Colorectal Cancer Clin. Cancer Res., November 1, 2000; 6(11): 4292 - 4299. [Abstract] [Full Text] [PDF]

				H. Shiomi, Y. Eguchi, T. Tani, M. Kodama, and T. Hattori Cellular Distribution and Clinical Value of Urokinase-Type Plasminogen Activator, Its Receptor, and Plasminogen Activator Inhibitor-2 in Esophageal Squamous Cell Carcinoma Am. J. Pathol., February 1, 2000; 156(2): 567 - 575. [Abstract] [Full Text] [PDF]

				C. Robert, I. Bolon, S. Gazzeri, S. Veyrenc, C. Brambilla, and E. Brambilla Expression of Plasminogen Activator Inhibitors 1 and 2 in Lung Cancer and Their Role in Tumor Progression Clin. Cancer Res., August 1, 1999; 5(8): 2094 - 2102. [Abstract] [Full Text] [PDF]

				G. Xiao, Y. E. Liu, R. Gentz, Q. A. Sang, J. Ni, I. D. Goldberg, and Y. E. Shi Suppression of breast cancer growth and metastasis by a serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cells PNAS, March 30, 1999; 96(7): 3700 - 3705. [Abstract] [Full Text] [PDF]

				G Cox, W P Steward, and K J O'Byrne The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer Thorax, February 1, 1999; 54(2): 169 - 179. [Full Text]

				S Suzuki, Y Hayashi, Y Wang, T Nakamura, Y Morita, K Kawasaki, K Ohta, N Aoyama, S R Kim, H Itoh, et al. Urokinase type plasminogen activator receptor expression in colorectal neoplasms Gut, December 1, 1998; 43(6): 798 - 805. [Abstract] [Full Text] [PDF]

				T. H. Bugge, K. W. Kombrinck, Q. Xiao, K. Holmback, C. C. Daugherty, D. P. Witte, and J. L. Degen Growth and Dissemination of Lewis Lung Carcinoma in Plasminogen-Deficient Mice Blood, December 1, 1997; 90(11): 4522 - 4531. [Abstract] [Full Text] [PDF]

				P. A. Pemberton, D. T. Wong, H. L. Gibson, M. C. Kiefer, P. A. Fitzpatrick, R. Sager, and P. J. Barr The Tumor Suppressor Maspin Does Not Undergo the Stressed to Relaxed Transition or Inhibit Trypsin-like Serine Proteases J. Biol. Chem., June 30, 1995; 270(26): 15832 - 15837. [Abstract] [Full Text] [PDF]